

SEQUENCE LISTING

<110> MIZUGUCHI, HIROYUKI
HAYAKAWA, TAKAO

<120> ADENOVIRUS VECTOR

<130> 081356/0163

<140> 09/845,160
<141> 2001-05-01

<150> JP 2001-131688
<151> 2001-04-27

<150> JP 2000-161577
<151> 2000-05-31

<160> 14

<170> PatentIn Ver. 2.1

<210> 1
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with heparan sulfate.

<400> 1
Lys Lys Lys Lys Lys Lys Lys
1 5

<210> 2
<211> 22
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with laminin receptor.

<400> 2
Thr Ser Gly Tyr Ile Gly Ser Arg Gly Tyr Ile Gly Ser Arg Gly Tyr
1 5 10 15

Ile Gly Ser Arg Ser Ser
20

<210> 3
<211> 16
<212> PRT
<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Peptide having affinity with laminin receptor.

<400> 3

Thr Ser Ala Ala Ser Ile Lys Val Ala Val Ser Ile Lys Val Ala Val
1 5 10 15

<210> 4

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with E-selectin.

<400> 4

Thr Arg Ser Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys Thr
1 5 10 15
Ser

<210> 5

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: RGD-4C peptide.

<400> 5

Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5

<210> 6

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: NGR associating peptide.

<400> 6

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys
1 5 10

<210> 7

<211> 81

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide 1.

<400> 7
aacaggagac acaacttcga acatcgatcc aagtgcatac tctatgtcat tttcatggga 60
ctggtctggc cacaactaca t 81

<210> 8
<211> 79
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide 2.

<400> 8
taatgttagtt gtggccagac cagtcggatg aaaatgacat agagtatgca cttggatcga 60
tggtcgaaat tgtgtctcc 79

<210> 9
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide 3.

<400> 9
cggttaattaa 10

<210> 10
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide 4.

<220>
<221> CDS
<222> (3)...(29)

<400> 10
cg aag tgt gac tgc cgc gga gac tgt ttc tg 31
Lys Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5 10

<210> 11
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide 5.

<400> 11
cgccagaaaca gtctccgcgg cagtcacact t 31

<210> 12
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide 6.

<400> 12
cggctgcaac ggccgctgctg tgagcggtctg cgccggccgc tg

42

<210> 13
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide 7.

<400> 13
cgcagcggcc ggcgcagccg ctcacgcagc ggccgttgca gc

42

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 14
Lys Cys Asp Cys Arg Gly Asp Cys Phe Cys
1 5 10